Oryzon Genomics Past Earnings Performance
Past criteria checks 0/6
Oryzon Genomics's earnings have been declining at an average annual rate of -0.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 8.5% per year.
Key information
-0.2%
Earnings growth rate
6.5%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 8.5% |
| Return on equity | -4.9% |
| Net Margin | -28.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Oryzon Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 16 | -5 | 4 | -5 |
| 30 Jun 24 | 12 | -4 | 4 | 0 |
| 31 Mar 24 | 15 | -3 | 4 | -2 |
| 31 Dec 23 | 16 | -4 | 4 | 0 |
| 30 Sep 23 | 17 | -4 | 3 | 0 |
| 30 Jun 23 | 17 | -4 | 4 | 0 |
| 31 Mar 23 | 17 | -5 | 4 | 0 |
| 31 Dec 22 | 17 | -5 | 4 | 0 |
| 30 Sep 22 | 10 | -3 | 4 | 1 |
| 30 Jun 22 | 14 | -5 | 3 | 0 |
| 31 Mar 22 | 12 | -5 | 4 | 0 |
| 31 Dec 21 | 12 | -5 | 4 | 0 |
| 30 Sep 21 | 11 | -4 | 5 | 1 |
| 30 Jun 21 | 10 | -4 | 5 | 0 |
| 31 Mar 21 | 7 | -5 | 5 | 4 |
| 31 Dec 20 | 12 | -4 | 5 | 0 |
| 30 Sep 20 | 12 | -4 | 4 | 0 |
| 30 Jun 20 | 13 | -4 | 4 | 0 |
| 31 Mar 20 | 13 | -4 | 4 | 0 |
| 31 Dec 19 | 12 | -4 | 4 | 0 |
| 30 Sep 19 | 10 | -4 | 4 | 0 |
| 30 Jun 19 | 9 | -4 | 4 | 0 |
| 31 Mar 19 | 8 | -2 | 3 | 0 |
| 31 Dec 18 | 8 | -1 | 4 | 0 |
| 30 Sep 18 | 7 | -2 | 4 | 0 |
| 30 Jun 18 | 6 | -2 | 4 | 0 |
| 31 Mar 18 | 6 | -6 | 4 | 0 |
| 31 Dec 17 | 5 | -6 | 4 | 0 |
| 30 Sep 17 | 6 | -6 | 4 | 0 |
| 30 Jun 17 | 6 | -6 | 3 | 0 |
| 31 Mar 17 | 5 | -6 | 3 | 0 |
| 31 Dec 16 | 5 | -6 | 3 | 0 |
| 30 Sep 16 | 6 | -5 | 3 | 0 |
| 30 Jun 16 | 6 | -4 | 2 | 0 |
| 31 Mar 16 | 8 | -1 | 3 | 0 |
| 31 Dec 15 | 8 | -1 | 2 | 0 |
| 30 Sep 15 | 8 | -1 | 2 | 0 |
| 30 Jun 15 | 7 | -1 | 2 | 0 |
| 31 Mar 15 | 11 | 2 | 2 | 0 |
| 31 Dec 14 | 19 | 8 | 2 | 0 |
| 31 Dec 13 | 3 | -3 | 2 | 0 |
Quality Earnings: 0RDB is currently unprofitable.
Growing Profit Margin: 0RDB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RDB is unprofitable, and losses have increased over the past 5 years at a rate of 0.2% per year.
Accelerating Growth: Unable to compare 0RDB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RDB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0RDB has a negative Return on Equity (-4.92%), as it is currently unprofitable.